# Evaluation of Botulinum TOXin Type a in the Treatment of Buerger's Disease

> **NCT05698979** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University Hospital, Toulouse** · enrollment: 8 (estimated)

## Conditions studied

- Buerger Disease
- Raynaud Syndrome

## Interventions

- **DRUG:** BOTOX INJECTION

## Key facts

- **NCT ID:** NCT05698979
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05698979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05698979, "Evaluation of Botulinum TOXin Type a in the Treatment of Buerger's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05698979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*